Supporting Information

HyPR-MS for multiplexed discovery of MALAT1, NEAT1, and NORAD IncRNA protein interactomes

Michele Spiniello^{1,6}, Rachel A. Knoener^{1,6}, Maisie I. Steinbrink^{1,2}, Bing Yang³, Anthony J. Cesnik¹, Katherine E. Buxton¹, Mark Scalf¹, David F. Jarrard^{2,3,4}, Lloyd M. Smith^{1,5,*}

¹ Department of Chemistry; University of Wisconsin – Madison; Madison, Wisconsin 53706; United States ² Molecular and Environmental Toxicology; University of Wisconsin – Madison; Madison, Wisconsin 53706; United States

³ Department of Urology; University of Wisconsin School of Medicine and Public Health; Madison, Wisconsin 53705; United States

⁴ Carbone Comprehensive Cancer Center; University of Wisconsin – Madison; Madison, Wisconsin 53792; United States

⁵ Genome Center of Wisconsin; University of Wisconsin – Madison; Madison, Wisconsin 53706; United States

⁶These authors contributed equally

*Correspondence: smith@chem.wisc.edu; Tel. 608-263-2594

Supporting Information:

HyPR-MS Protocol

Table S1: HyPR-MS Advances the Capabilities of In Vivo RNA Capture Technologies.

Figure S1: Determination of capture efficiencies and cell numbers required for protein detection. Table S2: Capture oligonucleotide (CO) and release oligonucleotide (RO) sequences and amounts used.

Table S3: Primer and probe sequences for qPCR assays.

Table S4: qPCR amplification parameters.

Figure S2. Capture efficiencies (CE) at each qPCR region for each target IncRNA.

Table S5: qPCR assay data statistics

Table S6. Protein Intensities and Fold Enrichments for MALAT1, NEAT1, and NORAD Protein Interactomes.

Table S7: Gene Ontology Term Enrichment Analysis for MALAT1, NEAT1, and NORAD protein interactomes.

Table S8: Summary of Validated Proteins

 Table S9:
 eCLIP Validation data analysis

HyPR-MS Protocol

Probe Design

- 1. Using available databases for IncRNAs (such as <u>https://lncipedia.org/db/search</u>), find the sequence of each target
- Load the sequence into the Mfold database (<u>http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form</u>)
 - a. Set the folding temperature to 37H (or whatever your desired hybridization temperature will be)
 - b. Leave all default parameters as they are
- 3. From the resulting single-strand frequency data, select regions with high values along several regions of the target RNA

Note: When studying specific isoforms, select only from regions that are specific to that isoform

Note: In general, we have found that 2-3 regions for capture is enough for an RNA less than 10 kb in length

- Find the complementary and reverse sequence (<u>http://www.bioinformatics.org/sms/rev_comp.htm</u>) to the chosen regions of the RNA target; this will be the sequence of the capture oligonucleotide (CO)
- 5. Use the OligoAnalyzer 3.1 from IDT (<u>https://eu.idtdna.com/calc/analyzer</u>) or other publicly available software to define necessary parameters for your CO conditions
 - a. Salt concentrations should be set to 375 mM (or the optimal concentration for hybridization)
 - b. Find the range of CO concentrations that are possible to obtain the ideal melting temperature (Tm) for your experiment

Note: The 'ideal' CO Tm is 20-28.5 higher than the hybridization temperature (in this case, 56.8-65.5). The optimal concentration of CO to use within this range will be tested in subsequent small-scale experiments.

Note: It is generally possible to meet the Tm by choosing a CO length of 20-30 nucleotides (shorter than this will not bind specifically to you target), finding single-stranded regions of the target RNA that have low GC content, using a lower probe concentration, or modifying the salt concentration.

6. After the desired CO sequence is found and the Tm range is met, add an 8 nt toehold sequence to the 5' end of the CO.

Note: This toehold should not affect the Tm for COs because it is not complementary to the target RNA, but it is important to include the toehold sequence when checking the formation of hairpins and self-dimerization (this can be done following the OligoAnalyzer 3.1 data analysis tips (<u>https://eu.idtdna.com/pages/support/technical-vault/faq/application/oligocharacteristics/how-do-i-use-the-oligoanalyzer-tool-to-analyze-possible-hairpinsand-dimers-formed-by-my-oligo-</u>) Note: It may be necessary to slightly shift COs to avoid formation of hairpins below the melting temperature, even if the single-stranded frequency from Mfold is not as high after this shift.

- a. Check the specificity of the CO to your target using NCBI BLAST
- 7. Create release oligonucleotides (ROs) that are reverse and complementary to the sequence of the COs for each target
- 8. Once all COs and ROs have been designed, use the OligoAnalyzer 3.1 software to check for heterodimer formation. Modify COs and ROs as necessary to reduce heterodimerization.

Small and Large Scale HyPR-MS Protocol

Materials

Reagents (all materials used prior to qPCR should be RNAse free)

Ice

Cells, 1% formaldehyde-treated for 10 minutes (small-scale: 5 x 10⁵ per condition; large-scale: 1 x 10[^]8 per bioreplicate) Ribonucleoside Vanadyl Complex (RVC) 200 mM Dithiothreitol, solid RNasin Plus Ribonuclease Inhibitor (Promega, Cat. No. N261B) Halt™ Protease Inhibitor Cocktail (100X) (Thermo Fisher Scientific, Cat. No. 78430) Lithium Chloride (LiCl) 8M Tris pH 7.5 4M Lithium Dodecyl Sulfate, solid (LiDS) Triton X-100 (10% w/v) Nuclease Free Water, not DEPC treated Capture oligonucleotides, biotinylated (at least one for each target and scrambled control, designed through IDT) Sera-Mag magnetic streptavidin microparticles (GE Healthcare, Cat. No. 30152105010150) Release oligonucleotides (complementary to each capture oligonucleotide, designed through IDT) Tris pH 8.0, 10 mM EDTA pH 8.0, 0.1 mM Proteinase K **TRI Reagent** Chloroform (100%) GlycoBlue[™] Coprecipitant (Invitrogen, Cat. No. AM9515) Ethanol (100% and 75%) Reverse Transcription Kit (Thermo Fisher Scientific, Cat. No. 4368814) LightCycler 480 Probes Master qPCR Kit (Roche, Cat. No. 04707494001) gPCR assays for several regions along each target (designed through IDT) Human Genomic DNA, mixed (Promega, Cat. No. G304A) Urea, solid Deoxycholic Acid, solid (DCA) HPLC water lodoacetamide, solid

Ammonium bicarbonate (200 mM and 50 mM) Sequencing Grade Modified Trypsin, lyophilized (Promega, Cat. No. V5111) Ethyl Acetate Trifluoroacetic Acid (TFA)

Equipment

Benchtop rocker Benchtop vortex mixer Mini-centrifuge Model 550 Sonic Dismembrator (Fisher Scientific) Benchtop centrifuge -80H freezer -20H freezer Nanodrop UV-Vis Spectrophotometer Incubator (37H) Thermocycler Roche LightCycler® 480 System Magnetic separation racks for 2 mL tubes Magnetic separation racks for 50 mL falcon tubes Pipets RNAse-free pipet tips 2 mL tubes, low-bind RNAse-free 50 mL conical falcon tubes, low-bind 50ml conical falcon tubes, low-bind RNAse-free 200 uL tubes RNAse-free RNaseZap[™] RNase Decontamination Wipes (Thermo Fisher Scientific, Cat. No. AM9786) Hot water bath (37H) Parafilm Bucket centrifuge Centrifugal filter units (50 kb filters) Savant Speed Vac Concentrator

Method

Each condition in the small-scale experiment requires 5×10^5 cells crosslinked with 1% formaldehyde for 10 minutes. An additional 40 uL aliquot is required to use as an input control. Several conditions can be tested at the same time during each experiment. Proteinase K treatment, RNA extraction, and RT-qPCR will be performed to measure capture efficiency (CE), selectivity (CS), release efficiency (RE) and fold enrichment (FE) (see main text). Based on these parameters, the best conditions and necessary number of cells to use in large-scale experiments will be determined.

Each large-scale experiment will be optimized based on results from small-scale experiments and scaled accordingly to meet the requirements for mass spectrometric analysis. The bulk of

each large-scale experimental sample will be subjected to protein purification, trypsin digestion and protein analysis, but small aliquots can be taken throughout and treated as the small-scale samples for quality assessment.

Lysis

- 1. Start the lysis procedure, using the following calculations to determine reagent volumes to add
 - a. Desired number of cells per uL lysate = 5000 cells
 - b. Pellet volume = 20 uL
 - c. Final volume = (total number of cells/5000) uL
 - d. RVC (200 mM) = [(Final volume*12.5)/200] uL
 - e. DTT (1 M) = [(Final volume*12.5)/1000] uL
 - f. RNAsin (40 U/mL) = [(Final volume/1000)*(125)/40)] uL
 - g. Protease Inhibitor (100X) = [(Final volume*1.25)/100] uL
 - h. LiCl (8 M) = [(Final volume*468.8)/8000]
 - i. Tris (4 M) = [(Final volume*62.5)/4000] uL
 - j. LiDS (10%) = [(Final volume*1.25)/10] uL
 - k. Triton X-100 (10%) = [(Final volume*1.25)/10] uL
 - I. Nuclease Free Water = remaining uL to achieve the final volume
- 2. Combine the above reagents with the cell pellet (placed in ice) and leave on ice for 10 minutes, vortexing periodically to break the pellet
- 3. Transfer the solution to a 2 mL low-bind tube (small-scale) or 50 mL falcon (large-scale).
- 4. Sonicate the lysate on ice to achieve an average chromatin fragmentation size of approximately 6kb (see Supplemental Information for gel image)
 - Note: This was achieved using a Fisher Scientific Model 550 Sonic Dismembrator pulsing 4 seconds on, 4 seconds off for 12 seconds at intensity 3 with a microtip (small-scale) or 24 seconds at intensity 4 with a full probe (largescale). Times and intensities may vary between sonicators.
- 5. Centrifuge at 4C, 1800 RPM for 2 minutes
- 6. Transfer the supernatant to a new low-bind tube and discard the pellet
- For each tested small-scale condition, add 100 uL of sonicated lysate (5 x 10⁵) to a separate low-bind RNAse free tube. For large-scale, transfer the lysate to a new lowbind 50 mL falcon. Discard pellets and place all tubes on ice.
 - a. At this point, reserve a 40 uL sample of lysate as an input control for capture quality assessment or mass spectrometry analysis.
 - b. Store any unused sonicated lysate at -80C for future experiments.

Hybridization

- 1. Add water to achieve 1.25x the lysate volume
- Add COs to fall within the range of Tm values established through IDT (small-scale), or an already-established optimal CO concentration (large-scale).

Note: If COs must be diluted to add the required amount, dilute in water

 Add the calculated amounts of CO to each condition and hybridize by rotating for 3 hours in an incubator at 37C Note: Treat the 40 uL input sample with the same temperature conditions as the other tubes. In this way, any degradation brought about by heat will be consistent across all samples and controls.

Buffer and Bead Preparation

1. During the 3 hour hybridization period, prepare the wash and release buffers in RNAsefree tubes

Wash Buffer	Final Conc.	Volume (uL)	Release Buffer	Final Conc.	Volume (uL)
LiCl	375 mM	46.9	LiCl	375 mM	46.9
Tris	50 mM	12.5	Tris	50 mM	12.5
LiDS	0.2%	20	LiDS	0.1%	10
Triton X-100	0.2%	20	Triton X-100	0.1%	10
H ₂ O		900.6	H₂O		920.6

- 2. 30 minutes before the end of hybridization, add streptavidin-modified magnetic beads to a 2 mL low-bind tube (small-scale) or a 50ml low-bind falcon (large-scale)
 - a. Use 2.2 uL of beads per picomole CO added for hybridization Note: It is important not to perform this step too far before hybridization is complete, or else the beads may spend too much time at room temperature and become less effective at capture
- 3. Put the tube of beads on the magnetic tube rack and wait 3-4 minutes to allow beads to leave the solution
- 4. Throw out the supernatant
- 5. Add wash buffer to the tube and resuspend the beads
 - a. Volume of wash buffer should be 5 times the volume of beads
- 6. Place the tube of beads on the shaker for 5 minutes
- 7. Put the tube with the beads on the magnetic tube rack for 3-4 minutes, then throw out the supernatant
- 8. Repeat steps 5-7 for a second wash
- 9. Resuspend the beads in their original volume with wash buffer

Bead Coupling

- 1. At the end of the hybridization period, add the required amount of beads to each sample Note: No beads are required for the 40 uL input sample, but it should still be heated and cooled in the same way as the other samples.
- 2. Return all samples and the input to the incubator at 37C for 1 hour

Elution

- 1. During the 1 hour incubation, prepare the ROs. For each target, use 100 times more RO than was added of its respective CO.
- 2. After the 1 hour incubation, put each condition on the magnetic tube rack for 3-4 minutes, and discard the supernatant
- 3. Resuspend the beads in wash buffer
 - a. Volume of wash buffer should be 5 times the volume of beads for each condition
- 4. Place samples on a shaker for 15 minutes at 37C
- 5. Put tubes with beads on the magnetic tube rack for 3-4 minutes, then throw out the supernatant
- 6. Resuspend the beads in release buffer
 - a. Volume of release buffer should be 3 times the volume of beads for each condition
- 7. Leave samples at room temperature for 5 minutes without shaking
- 8. Put tubes with beads on the magnetic tube rack for 3-4 minutes, then throw out the supernatant.
- 9. Resuspend the beads in release buffer
 - a. Volume of release buffer should be 3 times the volume of beads for each condition
- 10. Add the required amount of RO for the first target

Note: Because wash steps are performed between each target release, it may be desirable to release the target with the fewest number of copies first to avoid excess target loss.

- 11. Place the samples on a shaker for 30 minutes at room temperature to facilitate release Note: If the volume is too small for a benchtop shaker to mix thoroughly, use a foam tube holder attached to a vortex and shake on low
- 12. Put the tubes with beads on the magnetic tube rack for 3-4 minutes, then transfer the supernatant to a new tube and put in ice. This is the first captured sample.
 - Note: In small-scale experiments this entire sample will be subjected to Proteinase K treatment, RNA extraction and RT-qPCR for capture quality assessment. In large-scale a 40 uL aliquot will be taken from each captured sample to treat as the small-scale samples while the remaining captured sample will be stored overnight prior to eFASP protein purification.
- 13. Resuspend the beads in release buffer
 - a. Volume of release buffer should be 3 times the volume of beads for each condition
- 14. Put the tubes with beads on the magnetic tube rack for 3-4 minutes, then throw out the supernatant
- 15. Resuspend the beads in release buffer
 - a. Volume of release buffer should be 3 times the volume of beads for each condition
- 16. Repeat steps 10-15 to release each target and scrambled control sequentially Note: To test the elution efficiency, resuspend the beads in 3 times their original volume of release buffer after the final release step. Use no more than a 50 uL aliquot and check for the presence of each target RNA on the beads via

RT-qPCR (release efficiency).

Proteinase K Treatment and RNA Purification

The entirety of each input, captured, and various control samples taken from each small-scale, or their corresponding aliquots from large-scale, will be treated with Proteinase K and extracted. For the bulk of each large-scale captured sample, skip to the eFASP procedure.

- 1. Add Proteinase K and CaCl₂ to each aliquot to achieve a final concentration of 200 mM for each based on a 200 uL final volume.
- 2. To make reagent concentrations equal based on the respective buffers each sample was resuspended in, add the necessary reagents (LiCl, Tris, LiDS, etc.) to the tubes based on a 200 uL final volume.
- 3. Bring the resulting solutions to 200 uL with nuclease-free water, seal with parafilm, and digest overnight at 37H in a water bath
- 4. Begin RNA extraction by adding 500 uL Trizol to each sample
- 5. Vortex to resuspend the RNA and leave at room temperature for 5 minutes, vortexing periodically
- 6. Add 100 uL chloroform to each sample and shake vigorously to combine
- 7. Leave at room temperature for 5 minutes
- 8. Centrifuge at 4H, 12000 RCF for 10 minutes
- 9. While the samples are centrifuging, prepare new tubes for each sample containing 1.5 uL glycoblue in each
- 10. After centrifugation, take the upper layer of solution for each sample and add it to the tube containing glycoblue, making sure to note the volume
- 11. Add ethanol to these samples to achieve a final ethanol concentration of 75% in each
- 12. Store all samples at -20H overnight (10+ hours)
- 13. Centrifuge samples at 4H, max speed for 15 minutes
- 14. Discard the supernatant and resuspend the pellet in 750 uL of 75% ethanol
- 15. Centrifuge samples at room temperature, max speed for 8 minutes
- 16. Discard the supernatant, removing as much liquid as possible without disturbing the pellet, and let tubes dry for 5 minutes
- 17. Resuspend pellets in water (15-25 uL) and measure RNA concentrations with a NanoDrop
- 18. Use approximately 1 ug RNA from each sample (up to 10 uL) for RT-qPCR Note: To estimate the amount of DNA captured during the experiment, treat 1 ug of the input with reverse transcriptase (+) and another 1 ug without reverse Transcriptase (-). Any signal measured via qPCR from the second sample is genomic DNA and can be subtracted from the first for a more accurate measurement of capture efficiency.

Note: If qPCR assays have not been used before, follow the IDT PrimeTime qPCR Assay Resuspension Protocol and bring the stock concentration to 40x using IDTE buffer (10 mM Tris pH 8.0, 0.1 mM EDTA pH 8.0)

eFASP Procedure

1. Add solid urea to each of the captured, control, and small input samples to bring to a final concentration of 8M

Note: The solid urea will increase the final volume, sometimes by several mL. Take this into account when measuring final urea concentration.

- 2. Add enough DCA to achieve a final concentration of 2%
- 3. Vortex to mix
- 4. Take 50 kb filters and tubes for all samples and label them; 1 for the lysate sample and 4 for each captured/control sample
- 5. Put 450 uL of each solution into their respective filter
- 6. Centrifuge at room temperature, 14000 RCF for 10 minutes
- 7. Discard the eluent
- Repeat steps 5-7 until all the liquid from each sample has been filtered Note: If at any step during the eFASP procedure the liquid does not completely flow through the filter into the collection tube after centrifugation, repeat the centrifugation step
- 9. During this time, create buffers for the rest of the eFASP procedure

Exchange Buffer	Final Buffer Concentration	Volume
Urea (solid)	8 M	24 g
DCA (solid)	0.10%	50 mg
Add water to final volume:		50 mL

Reducing Buffer	Final Buffer Concentration	Volume
Urea (solid)	8 M	4.8 g
DTT	20 mM	200 uL
Add water to final volume:		10 mL

Alkylation Buffer	Final Buffer Concentration	Volume
Urea (solid)	8 M	24 g
Iodoacetamide (solid)	50 mM	0.462 g
Ammonium Bicarbonate	50 mM	12.5 mL

(200 mM)	
Add water to final volume:	50 mL

Digestion Buffer	Final Buffer Concentration	Volume	
Urea (solid)	1 M	3 g	
Ammonium Bicarbonate (200 mM)	50 mM	12.5 mL	
DCA (solid)	0.10%	50 mg	
Add water to final volume		50 mL	

10. After all the samples have been filtered, add 400 uL exchange buffer to each filter

- 11. Centrifuge at room temperature, 14000 RCF for 10 minutes
- 12. Discard the eluent
- 13. Repeat steps 10-13 two more times
- 14. Add 200 uL reducing buffer to each filter and incubate on the benchtop at room temperature for 30 minutes
- 15. Centrifuge samples at room temperature, 14000 RCF for 10 minutes
- 16. Discard the eluent
- 17. Add 200 uL alkylation buffer to each filter and incubate in the dark at room temperature for 30 minutes
- 18. Centrifuge samples at room temperature, 14000 RCF for 10 minutes
- 19. Discard the eluent
- 20. Add 400 uL digestion buffer to each filter
- 21. Centrifuge samples at room temperature, 14000 RCF for 10 minutes
- 22. Discard the eluent
- 23. Repeat steps 20-22 two more times
- 24. Move the filters into a clean collection tube
- 25. Add 100 uL digestion buffer and 1 ug trypsin to each filter
- 26. Close and wrap each tube with parafilm, incubate overnight at 37C without rotation
- 27. After incubation, remove parafilm and centrifuge samples at room temperature, 14000 RCF for 10 minutes

Note: This has eluted the proteins - do not discard the eluent!

- 28. Add 50 uL of 50 mM ammonium bicarbonate
- 29. Centrifuge samples at room temperature, 14000 RCF for 10 minutes
- 30. Transfer eluent to new snap-top tubes, noting the volume of each
- 31. Add 200 uL ethyl acetate to each tube
- 32. Add TFA to bring each sample to 0.5%
- 33. Shake manually for 1 minute, then centrifuge at room temperature, 15700 RCF for 2 minutes

- 34. Discard the top layer
- 35. Add 200 uL ethyl acetate to each tube and shake manually for 1 minute
- 36. Centrifuge at room temperature, 15700 RCF for 2 minutes
- 37. Discard the top layer
- 38. Repeat steps 35-37 once more
- 39. Place all tubes (open) in a Speed Vac and spin until samples are completely dry and store at -80C until ZipTip can be performed

Table S1: HyPR-MS Advances the Capabilities of *In Vivo* RNA Capture Technologies.

	CHART	ChIRP	RAP-MS	HyPR-MS
	(West et al., 2014)	(Chu et al., 2015)	(McHugh et al., 2015)	
Capture Oligonucleotide	RNAse H Assay A: Able to design the	Full RNA Tiling A: Avoid location bias	Full RNA Tiling A: Avoid location bias	Secondary-structure prediction software
Design	capture oligonucleotide to hybridize to the optimal location of the target RNA using empirical evidence of where the single stranded regions are. L: Expensive and	caused from using only one capture oligonucleotide by using many oligonucleotides that hybridize along the full length of the target RNA. L: Expensive. Unable to	caused from using only one capture oligonucleotide by using many oligonucleotides that hybridize along the full length of the target RNA. L: Expensive. Unable to	A: Mfold software (Zuker et al., 2003) uses minimum free energy estimations to predict nucleotide regions with the highest probability to be single stranded. 2-3 oligonucleotides complementary to these regions produces sufficient
	laborious. Using only isolate different iso	isolate different isoforms of the RNA because the full sequence is hybridized to the	s isolate different isoforms	capture efficiency along the length of the target RNA. Faster and less expensive than RNAse H Assay and Full RNA Tiling. Allows for isolation of isoforms. Reduced location bias than using only one oligonucleotide for capture.
				L: Secondary structure is only a prediction, not empirically determined.
Crosslinking	3% formaldehyde, 30	3% formaldehyde, 30	UV-crosslinking	1% formaldehyde, 10 min.
Conditions	 min. A: Identification of direct and indirect protein-RNA interactions critical to RNA processing (Schmitz et al., 2016). Applied with success in many applications such as PICh and HyCCAPP. L: Formaldehyde may cause single- and double- stranded breaks in nucleic acids (Grafstrom et al., 1984, Kondo et al., 1985) resulting in the target RNA potentially being fragmented. This is problematic if only one oligonucleotide is used for capture. 	nucleic acids (Grafstrom et al., 1984, Kondo et al., 1985) resulting in the target RNA potentially being fragmented. This is not problematic for Full	 A: Crosslinks only direct RNA-protein interactions which could be desirable in some applications. Milder solubilization and less target fragmentation risk. L: For discovery and understanding of RNA interactomes it is beneficial to find indirect interactors as their impact on processing is significant. (Schmitz et al., 2016). Low efficiency of crosslinking which could correspond to excessive false negatives. 	A: Same advantages as those for CHART and ChIRP however the limited exposure to formaldehyde here reduces the risk of RNA fragmentation and also reduces the amount of sonication necessary for nucleic acid solubilization downstream which also reduces RNA fragmentation. This is critical for the use of only a few capture oligonucleotides to capture the full RNA sequence without using the Full RNA Tiling capture strategy.

(In reference to the Results section and Table 1; A=Advantage, L=Limitation)

	CHART (West et al., 2014)	ChIRP (Chu et al., 2015)	RAP-MS (McHugh et al., 2015)	HyPR-MS
Lysate Solubilization and DNA Fragment Size	Sonication; 2-10 kilobases A: Sonication fragments and solubilizes the DNA so that IncRNAs that are associated with the chromatin can be isolated from the full genome. L: Excessive sonication can cause target RNA fragmentation (see above).	Sonication; 200-500 bases A: Sonication fragments and solubilizes the DNA so that IncRNAs that are associated with the chromatin can be isolated from the full genome. L: Excessive sonication can cause target RNA fragmentation (see above).	Sonication; unspecified A: Sonication fragments and solubilizes the DNA so that IncRNAs that are associated with the chromatin can be isolated from the full genome. L: Excessive sonication can cause target RNA fragmentation (see above).	Sonication; about 6 kilobases A: Sonication fragments and solubilizes the DNA so that IncRNAs that are associated with the chromatin can be isolated from the full genome. Milder sonication is sufficient for HyPR-MS, because of reduced crosslinking, thus preserving the target RNA integrity. L: Excessive sonication can cause target RNA fragmentation (see above).
Elution Strategy	RNAse H L: only one RNA target per 10 ⁸ cells.	Heat and Biotin Elution L: only one RNA target per 10 ⁸ cells.	RNAse and DNAse Digestion L: only one RNA target per 10 ⁸ cells.	Toehold-Mediated Release (Kennedy-Darling et al., 2014) Allows for isolation of several RNA targets from the same 10 ⁸ cells. Dramatically decreasing the time, cost, and background variability between each RNA target captured. See Figure 1B for mechanism.




Figure S1: Determination of capture efficiencies and cell numbers required for protein detection.

(In reference to the Results section and Figure 2A and 2B) (A) Two COs and three RT-qPCR assays were designed for NEAT1 and MALAT1 capture. Three COs and four RT-qPCR assays were designed for NORAD capture. (Tables S2 and S3). The efficiency of capture was assessed for captures using multiple COs (All listed in Tables S2) and for captures using only one CO (5'-NORAD, 5'-NEAT, and 5'MALAT1-001 COs were used for the captures for "One CO" efficiency calculations. Capture efficiency is defined here as the percentage of the target IncRNA transcripts that were captured and released from the beads relative to the amount available for capture in the lysate sample. The amount of target in each sample was determined using multiple gPCR assays (Table S3) that amplified various regions along each target IncRNA: near the 5'-end, towards the middle, and near the 3'-end (Figure 2A). The results here show that when using only one CO per RNA target the gPCR amplification declines at regions further from the location of the CO. The data shows that using multiple capture oligonucleotides reduces this effect and that the capture efficiencies at each location along the RNA exceed the calculated minimum efficiency thresholds for each target. For assessment of the variability in capture efficiencies, see Results, Capture Efficiency (B) The number of cells necessary to obtain sufficient protein for one capture experiment was determined using the estimated copy number of each IncRNA transcript, the estimated detection limit for a protein in a complex biological mixture, and the capture efficiency of each IncRNA as determined from small scale experiments. Then, using the determined cell number, a minimum capture efficiency threshold was calculated for each target. This threshold was used to ensure that the actual capture efficiencies calculated from each qPCR measured region of the large-scale capture experiments is sufficient to detect by MS even low abundance proteins. These efficiencies are indicated in the graphs in panel A as grey boxes. The multiple-CO captures provide sufficient copies of each target IncRNA to

surpass the capture efficiency threshold established above, while still allowing the isolation of specific isoforms of a given IncRNA.

Target	Capture Oligonucleotide Sequence 5'-3' (toehold in red)	Amount of CO used (pmol)	Release Oligonucleotide Sequence 5'-3' (toehold in red)	Amount of RO used (nmol)
5`-MALAT1 - 001	TCGTATCTCAATATTTTCA TTTTCTATCTTGTTTCTAT	75	ATAGAAACAAGATAGAAA ATGAAAATATTG <mark>AGATAC GA</mark>	7.5
3`-MALAT1 - 001	TCGTATCTCACCCAGCAT TACAGTTCTT	75	AAGAACTGTAATGCTGG GTG <mark>AGATACGA</mark>	7.5
5`-NEAT1	TCGTATCTAAGTTATTTC ATCAGGCTAAGAA	357	TTCTTAGCCTGATGAAAT AACTT <mark>AGATACGA</mark>	35.7
3`-NEAT1	ТССТАТСТСАААСАТТСА ААТТАААААТАСААТАААТ	178.5	ATTTATTGTATTTTTAATT TGAATGTTTG <mark>AGATACGA</mark>	17.9
5`-NORAD	TCGTATCTAGCTTTTTCA TATTATATACACAG	178.5	CTGTGTATATAATATGAA AAAGCT <mark>AGATACGA</mark>	17.9
NORAD Middle	TCGTATCTAATGGTTATA TCTGATAGTGTCTT	178.5	AAGACACTATCAGATATA ACCATT <mark>AGATACGA</mark>	17.9
3`-NORAD	CAACTGTCACATCAATGG CTATCAAAATGTAAATAT GG	178.5	CCATATTTACATTTTGATA GCCATTGATGTGACAGTT G	17.9
Scrambled	CAACTGTCGCGTCTTTAT TTAGTTTACTCTTGATTGT T	75	AACAATCAAGAGTAAACT AAATAAAGACGCGACAGT TG	7.5

Table S2: Capture oligonucleotide (CO) and release oligonucleotide (RO) sequences and amounts used. (In reference to the Results section and Figure 2A).

Table S3: Primer and probe sequences for qPCR assays. (In reference to Results section and Figure 2A).

Target	Forward 5'-3'	Probe 5'-3'	Reverse 5'-3'
5`-MALAT1-001	CAGGATTCCAGGAACCA	CTAGGACTGAGGAGCAA	TTCCTATCTTCACCACGA
	GTG	GCGAGC	ACTG
MALAT1-001 Middle	GAACGAATGTAACTTTAA	TCCAGGCACATGGCAAT	GATCATAATCTCCCACCT
	GGCAGG	AGAGGC	GTCTAAG
3`-MALAT1-001	ACGTATTGTTTTCTCAGG	AAAGATGCTGGTGGTTG	GATTTGAACCCCGTCCT
	TTTTGC	GCACTC	GG
5`-NEAT1	GCCTCCGGTCATACTAG	CCTTGTAGATGGAGCTT	AGGTGGGTAGGTGAGAG
	TTTTG	GCAGATGGA	G
NEAT1-Middle	CACCTAAAATCAGTTTGG	CTCTCCCCACAATCCCC	AGGTGGGTAGGTGAGAG
	AAAACAAG	ATCCC	G
3`-NEAT1	CACCTAAAATCAGTTTGG	CTCTCCCCACAATCCCC	ACATGTAGTAAAGGCAC
	AAAACAAG	ATCCC	CTCG
5`-NORAD	TGGCTGTGCCCAGACCT	CCACGGCCGCCATTAGT	CAGCGAACCTCTCTTTCC
	Т	С	CACCC
5`/Middle-NORAD	CACGTTTGTTAAGTGGGT	ACATGGAGCTGGAAGAC	AATATGACCAGTCTAGCA
	TAGATG	CTGAGAAG	TAGAACC
3`/Middle-NORAD	GACACGTGCCTATATCC	CCTTCCAACTCCTCTCCA	CTTCTAAATACGAACATT
	ATCAG	CCACC	CTGGTCTAG
3`-NORAD	TTGTTAAGCCACCTCTGA	TGCCAACCTAATGAACAA	CCTGTATAATTCCTTCTG
	GC	GTCCTGACA	CCCC

Table S4: qPCR amplification parameters.	(In reference to Methods section)
------------------------------------------	-----------------------------------

Program	Cycles	Temp (B)	Acquisition Mode	Analysis Mode	Hold	Ramp Rate (B/s)
Pre-Incubation	1	95	None	None	8 min	4.4
Amplification	45	95	None	Quantification	10 sec	4.4
	45	57	None	Quantification	20 sec	2.2
	45	72	Single	Quantification	1 sec	4.4
Cool	1	40	None	None	10 sec	2.2




Figure S2. (In reference to Figure 2) (A) Capture efficiencies (CE) at each gPCR region for each target IncRNA. There are differences in the CE measurement at different regions of the same IncRNA. These differences could be due to the secondary structure of the RNA or the protein occupancy at the capture region of the IncRNA, resulting in fewer captured molecules of the target RNA, or the variable efficiencies of the RT-qPCR assays in complex samples. It is also an artifact of the experimental design; up to a certain point, increases in CO concentration during hybridization can increase the CE (data not shown), and this must be optimized for each target IncRNA. However, the volume of streptavidin-coated beads needed, and thus a large portion of the cost of the experiment, also increases with increasing CO concentration. For this reason, the concentration of each CO added to the capture experiment was determined to ensure that the CE would surpass the calculated CE threshold (Figure S1B), but not necessarily to maximize the CE for each region (see Table S2 for concentrations used). (B) DNA capture efficiencies (CE). Each CO can hybridize not only the target IncRNA, but also its corresponding DNA sequence, meaning any proteins interacting with that region of the genome could be falsely identified as RNA interactors. To ensure this had minimal effect on the overall protein content of each capture sample, the DNA CE was found by measuring the number of DNA copies corresponding to the target RNA sequence in the captured sample and comparing it to the number of copies in the lysate. Based on DNA CE values that are consistently lower than 0.1%, the small total DNA copy number (two copies per cell), and the mass spectrometry sensitivity (approximately 3 femtomole, or 1.8 x 10⁹ copies), any contamination by DNA-interacting proteins is not able to affect the specificity of the RNA captures.